Developing new drugs to target a cancer-related protein in colorectal cancer
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
This study is looking at a protein called GSTO1 that makes it harder for colorectal cancer treatments to work, and the researchers are trying to create new drugs that can target and break down this protein to help improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10894081 on NIH RePORTER |
What this research studies
This research focuses on a protein called GSTO1, which is found in high levels in colorectal cancer and contributes to drug resistance. The team is using advanced genetic techniques, including CRISPR and bioinformatics, to create and test new small-molecule drugs that can effectively target and degrade GSTO1. By understanding how GSTO1 functions in cancer cells, they aim to develop treatments that can overcome resistance and improve patient outcomes. The research includes both laboratory experiments and analysis of cancer cell behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer, particularly those who have shown resistance to current treatments.
Not a fit: Patients with non-colorectal cancers or those who are not currently undergoing treatment for cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment effectiveness for colorectal cancer patients.
How similar studies have performed: Other research has successfully targeted similar proteins in cancer treatment, suggesting a promising avenue for this approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Neamati, Nouri — University of Michigan at Ann Arbor
- Study coordinator: Neamati, Nouri
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.